SenseGuard (946598)

  https://cordis.europa.eu/project/id/946598

  Horizon 2020 (2014-2020)

  A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

  SME instrument (EIC-SMEInst-2018-2020)

  internet of things  ·  public health  ·  coronaviruses  ·  sensors

  2020-04-01 Start Date (YY-MM-DD)

  2023-03-31 End Date (YY-MM-DD)

  € 3,567,185 Total Cost

  Description

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become one of the leading causes of death by 2030. Nevertheless, COPD patients lack of a constant and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems. SenseGuard is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing. NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes and is run by an experienced and multi-disciplinary team of 12 people. During the proposed Phase 2 project, NanoVation will finalise the development of the SenseGuard device and validate its efficacy and safety in dedicated clinical studies.

  Complicit Organisations

1 Israeli organisation participates in SenseGuard.